- Generic name
- Rabeprazole Sodium
- Strength
- 20 mg
- Dosage form
- Tablet
- Manufactured by
- Bengal Drugs & Chemical Works Pharm. Ltd.
Digerab-20 Tablet
About Digerab-20 Tablet
Digerab-20 20 mg tablet is a medicine made by Bengal Drugs & Chemical Works Pharm. Ltd. It is not for immediate relief of every stomach upset; a doctor should confirm the reason for symptoms before treatment.
There are 48 brands of Rabeprazole Sodium listed in Bangladesh. The lowest listed price is Acifix 10 mg Sprinkle Capsule at ৳ 3.50 per unit.
What is Digerab-20 Tablet?
Made by Bengal Drugs & Chemical Works Pharm. Ltd., Digerab-20 is a tablet whose active ingredient is Rabeprazole Sodium. It contains Rabeprazole Sodium, a proton pump inhibitor, and is supplied as a 20 mg enteric-coated capsule. The capsule is enteric coated, which protects the medicine until it reaches the intestine. The doctor decides the dose and course of treatment.
Uses of Digerab-20
It is not for immediate relief of every stomach upset; a doctor should confirm the reason for symptoms before treatment. Digerab-20 is used in adults to treat active duodenal ulcer and active benign gastric ulcer. Your doctor will decide whether this medicine is suitable for your condition.
How to use Digerab-20
The dose, timing and length of the course are decided by the doctor and may differ from person to person. Swallow the tablet with water. Digerab-20 is taken by mouth. Do not change the dose or stop early without asking your doctor, even if you feel better. Do not stop early just because you feel better, and do not share the medicine with anyone else.
Side effects of Digerab-20
Digerab-20 is generally well tolerated. Seek medical advice for any unusual or severe symptom while taking this medicine. Most people tolerate the medicine well, but if you experience any side effects, contact your doctor. Contact your doctor if a side effect is severe, does not settle, or worries you, and seek urgent help for any serious reaction. Ask your doctor or pharmacist about anything you are unsure of.
Safety and precautions
Rabeprazole is not to be used by anyone allergic to it or to the other ingredients, and it is not used in pregnancy or during breastfeeding. Your doctor should rule out stomach or food-pipe cancer before treatment, since relief of symptoms does not exclude it. If you take long-term treatment, especially for more than a year, you should be monitored regularly. Tell your doctor before starting if you are pregnant, could be pregnant or are nursing.
Frequently asked questions
What does Digerab-20 treat?
It is not for immediate relief of every stomach upset; a doctor should confirm the reason for symptoms before treatment. Digerab-20 is used in adults to treat active duodenal ulcer and active benign gastric ulcer.
How do I use Digerab-20 correctly?
The dose, timing and length of the course are decided by the doctor and may differ from person to person. Swallow the tablet with water.
What are the side effects of Digerab-20?
Digerab-20 is generally well tolerated. Seek medical advice for any unusual or severe symptom while taking this medicine.
Is Digerab-20 safe for everyone?
Rabeprazole is not to be used by anyone allergic to it or to the other ingredients, and it is not used in pregnancy or during breastfeeding. Your doctor should rule out stomach or food-pipe cancer before treatment, since relief of symptoms does not exclude it.
Indications
- Active duodenal ulcer
- Active benign gastric ulcer
- Symptomatic erosive or ulcerative gastro-esophageal reflux disease (GERD).
- Gastro-esophageal Reflux Disease Long-term Management (GERD Maintenance) ... Read more
- Active duodenal ulcer
- Active benign gastric ulcer
- Symptomatic erosive or ulcerative gastro-esophageal reflux disease (GERD).
- Gastro-esophageal Reflux Disease Long-term Management (GERD Maintenance)
- Symptomatic treatment of moderate to very severe gastro-esophageal reflux disease (symptomatic GERD)
- Zollinger-Ellison Syndrome
- In combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori in patients with peptic ulcer disease.
Pharmacology
Dosage & Administration
Erosive or Ulcerative Gastro-Esophageal Reflux Disease (GERD): The recommended oral dose for this condition is 20 mg to be taken once daily for four to eight weeks.
Gastro-Esophageal Reflux Disease Long-term Management (GERD Maintenance): For long-term management, a maintenance dose of rabeprazole sodium 20 mg or 10 mg once daily can be used depending upon patient response.
Symptomatic treatment of moderate to very severe Gastro-Esophageal Reflux Disease (symptomatic GERD): 10 mg once daily in patients without oesophagitis. If symptom control has not been achieved during four weeks, the patient should be further investigated. Once symptoms have resolved, subsequent symptom control can be achieved using an on-demand regimen taking 10 mg once daily when needed.
Treatment of GERD in pediatric patients 1 to 11 years of age (Less than 15 kg): 5 mg once daily for 12 weeks with the option to increase to 10 mg if inadequate response.
Treatment of GERD in pediatric patients 1 to 11 years of age (15 kg or more): 10 mg once daily for 12 weeks.
Zollinger-Ellison Syndrome: The recommended adult starting dose is 60 mg once a day. The dose may be titrated upwards to 120 mg/day based on individual patient needs. Single daily doses up to 100 mg/day may be given. 120 mg dose may require divided doses, 60 mg twice daily. Treatment should continue for as long as clinically indicated.
Eradication of H. pylori: Patients with H. pylori infection should be treated with eradication therapy. The following combination given for 7 days is recommended. Rabeprazole sodium 20 mg twice daily, clarithromycin 500 mg twice daily and amoxicillin 1g twice daily.
Interaction
Contraindications
Side Effects
Pregnancy & Lactation
Precautions & Warnings
- Symptomatic response to therapy with Rabeprazole does not preclude the presence of gastric or oesophageal malignancy, therefore the possibility of malignancy should be excluded prior to commencing treatment with Rabeprazole 20 mg Gastro-resistant Tablets.
- Patients on long-term treatment (particularly those treated for more than a year) should be kept under regular surveillance.
- Proton pump inhibitors, especially if used in high doses and over long durations (>1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly or in presence of other recognised risk factors. Observational studies suggest that proton pump inhibitors may increase the overall risk of fracture by 10–40%. Some of this increase may be due to other risk factors. Patients at risk of osteoporosis should receive care and they should have an adequate intake of vitamin D and calcium.
- A risk of cross-hypersensitivity reactions with other proton pump inhibitor or substituted benzimidazoles cannot be excluded.
- Patients should be cautioned that Rabeprazole gastro-resistant tablets should not be chewed or crushed, but should be swallowed whole.
- There have been post marketing reports of blood dyscrasias (thrombocytopenia and neutropenia). In the majority of cases where an alternative aetiology cannot be identified, the events were uncomplicated and resolved on discontinuation of rabeprazole.
- Hepatic enzyme abnormalities have been seen in clinical trials and have also been reported since market authorisation. In the majority of cases where an alternative aetiology cannot be identified, the events were uncomplicated and resolved on discontinuation of rabeprazole.
- No evidence of significant drug related safety problems was seen in a study of patients with mild to moderate hepatic impairment versus normal age and sex matched controls. However because there are no clinical data on the use of rabeprazole in the treatment of patients with severe hepatic dysfunction the prescriber is advised to exercise caution when treatment with Rabeprazole 20mg Gastro-resistant. Tablets is first initiated in such patients.
- Co-administration of atazanavir with Rabeprazole is not recommended.
- Treatment with proton pump inhibitors, including rabeprazole, may possibly increase the risk of gastrointestinal infections such as Salmonella, Campylobacter and Clostridium difficile.
Influence on vitamin B12 absorption: Rabeprazole sodium, as all acid-blocking medicines, may reduce the absorption of vitamin B12 (cyanocobalamin) due to hypo- or a- chlorhydria. This should be considered in patients with reduced body stores or risk factors for reduced vitamin B12 absorption on long-term therapy or if respective clinical symptoms are observed.
Subacute cutaneous lupus erythematosus (SCLE): Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping Rabeprazole. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.
Interference with laboratory tests: Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, Rabeprazole 20mg Gastro-resistant Tablets treatment should be stopped for at least 5 days before CgA measurements. If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment.
Overdose Effects
Storage Conditions
Alternative brands of Rabeprazole Sodium
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.